Warning on Amgen drugs.The U.S. Food and Drug Administration issued a warning regarding Amgen Inc.'s drugs Aranesp and Epogen E·po·gen A trademark for the drug epoetin alfa. epoetin alfa Epogen, Eprex (CA) (UK), Procrit Pharmacologic class: Recombinant human erythropoietin Therapeutic class: , warning that they could cause a blood condition called aplasia aplasia /apla·sia/ (ah-pla´zhah) lack of development of an organ or tissue.aplas´tic aplasia axia´lis extracortica´lis conge´nita familial centrolobar sclerosis. . The two drugs were the best selling treatments for Thousand Oaks-based Amgen last year, with combined sales of $5.1 billion. Before presstime press·time n. The time at which a publication, especially a newspaper, is submitted for printing. on Friday morning, shares of Amgen were down more than 2 percent. Johnson & Johnson in New Jersey was also named in the warning for its anemia anemia (ənē`mēə), condition in which the concentration of hemoglobin in the circulating blood is below normal. Such a condition is caused by a deficient number of erythrocytes (red blood cells), an abnormally low level of hemoglobin drug Procrit. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion